登录新浪财经APP 搜索【信披】查看更多考评等级 此次合作延续双方2024年以来70亿美元级合作，助力阿斯利康补齐管线，推动中国创新药从"产品出 海"升级为"技术输出"，重塑全球赛道格局。 （本文不构成任何投资建议，信息披露内容以公司公告为准。投资者据此操作，风险自担。） 2026年1月30日，石药集团（01093.HK）与阿斯利康达成战略合作，潜在交易额185亿美元，彰显中国 创新药技术全球认可度。 双方依托石药月给药缓释技术、AI多肽发现两大平台，合作开发8个体重管理创新项目，含1个即将进 入I期临床的SYH2082双靶点激动剂，及3个临床前项目及4个新增项目。 石药获12亿美元预付款，及最高35亿研发、138亿销售里程碑付款与双位数销售提成。阿斯利康获大中 华区外全球独家权益，石药保留本土权益，形成"本土研发 + 全球商业化"模式。 ...

石药集团则将获得12亿美元的预付款、最高35亿美元的研发里程碑付款、138亿美元的销售里程碑付 款，以及最高达双位数比例的销售提成。此次合作也创下GLP-1赛道海外BD交易的新纪录。 据介绍，此次合作标的长效技术可实现多肽药物的缓释，使给药间隔达到每月一次或更长。AI技术台 可以针对药物靶点快速设计及筛选候选分子，在药效、选择性与信号偏向性等维度进行系统优化。 但资本市场反应却一反常态。截至发稿，石药集团港股股价跌超11%。 研发实力的稳步提升，也推动石药集团创新管线加速兑现。财报显示，截至2025年9月底，其已落地4笔 BD交易，累计实现授权收入15.40亿元。 值得一提的是，阿斯利康与石药集团已达成多次合作。早在2024年10月，双方就签订独家许可协议，推 进Lp(a)干扰剂YS2302018的开发。后又在去年6月宣布共同开发新型口服小分子候选药物，潜在交易总 金额达53.3亿美元。 1月30日，石药集团在港交所发布公告，宣布与阿斯利康达成协议，将利用其专有的缓释给药技术平台 及多肽药物AI发现平台，开发创新长效多肽药物，合作潜在交易价值高达185亿美元。 而石药集团之所以能持续获得阿斯利康青睐，离不开其 ...

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca aims to develop innovative long-acting peptide drugs, leveraging CSPC's proprietary drug delivery technology and AI discovery platform, with a potential total value of up to $18.5 billion [2][5][6]. Group 1: Collaboration Details - CSPC has signed a strategic R&D collaboration and licensing agreement with AstraZeneca, which includes a $1.2 billion upfront payment and potential milestone payments of up to $3.5 billion for R&D and $13.8 billion for sales [2][5]. - AstraZeneca will gain exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize a weight management product portfolio, including the clinical-ready project SYH2082 [5][6]. - The collaboration will also focus on developing four additional projects based on CSPC's technology platforms [5]. Group 2: Market Potential - The global obesity issue is projected to escalate, with over 2.9 billion adults expected to be classified as having a high BMI by 2030, driving demand for GLP-1 receptor agonists [6][7]. - The GLP-1RA market is anticipated to reach a valuation of $100 billion by 2030, attracting significant interest from pharmaceutical companies [7][8]. - Existing GLP-1 drugs have shown substantial revenue growth, with Eli Lilly's drug generating $24.837 billion in revenue in the first three quarters of 2025, accounting for 54% of its total revenue [6][7]. Group 3: Competitive Landscape - The GLP-1 market is transitioning from an early "blue ocean" phase to a competitive landscape dominated by major players like Novo Nordisk and Eli Lilly, with ongoing opportunities for differentiation and innovation [7][8]. - Current trends in GLP-1 drug development are focusing on multi-target approaches, longer efficacy, and more convenient administration methods, with oral formulations becoming a key competitive focus [7][8]. Group 4: Financial Context - CSPC's recent collaborations are part of a broader trend in the biopharmaceutical sector, where partnerships are increasingly seen as a means to enhance cash flow and support ongoing R&D efforts [11][12]. - Despite recent collaborations, CSPC has faced financial pressures, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [12].

Core Viewpoint - The stock of CSPC Pharmaceutical Group (1093.HK) experienced a significant decline of 12.54%, closing at HKD 9.35, with trading volume exceeding HKD 3.8 billion following the announcement of a strategic research and development collaboration with AstraZeneca [1] Group 1: Company Developments - CSPC Pharmaceutical Group has signed a strategic research and development collaboration and licensing agreement with AstraZeneca to utilize its proprietary sustained-release drug delivery technology platform and AI discovery platform for innovative long-acting peptide drugs [1] - The agreement entails comprehensive strategic cooperation between CSPC and AstraZeneca in the discovery of innovative peptide molecules and the development of long-acting delivery products [1] - CSPC will continue to advance its existing preclinical long-acting peptide pipeline while also discovering and developing other innovative long-acting peptide products for AstraZeneca [1]

Core Insights - AstraZeneca has announced a strategic partnership with CSPC Pharmaceutical Group, involving an upfront payment of $1.2 billion and a potential total deal value exceeding $18.5 billion [2][3] Group 1: Partnership Details - The collaboration focuses on developing innovative long-acting peptide drugs using CSPC's proprietary sustained-release drug delivery technology and AI drug discovery platform [2] - CSPC's long-acting technology allows for monthly or longer dosing intervals, enhancing patient compliance for long-term medication [2] - The partnership includes the overseas rights for a weight management product, SYH2082, which is a long-acting GLP-1R/GIPR agonist currently advancing to Phase I clinical trials, along with three preclinical projects targeting obesity and weight-related issues [2][3] Group 2: Financial Implications - CSPC will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for R&D and up to $13.8 billion for sales, plus a double-digit percentage royalty on net sales of the licensed products [3] - The global competition in GLP-1 development has intensified, with pharmaceutical companies focusing on next-generation weight loss therapies that improve patient experience and efficacy [3] Group 3: Previous Collaborations - This is not the first collaboration between AstraZeneca and CSPC; they previously established a partnership in June 2025 with a potential value exceeding $5 billion, focusing on AI-driven oral small molecule drug development for chronic and immune diseases [4] - AstraZeneca plans to invest over 100 billion RMB (approximately $15 billion) in China by 2030 to expand its presence in drug production and R&D [4]

Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has fallen over 10%, currently down 9.07% at HKD 9.72, with a trading volume of HKD 25.63 billion [1] Group 1: Strategic Partnership - CSPC Pharmaceutical Group announced a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] - The collaboration includes a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects, with plans to explore four additional new projects [1] Group 2: Financial Implications - The licensing agreement sets a new record for overseas business development transactions in the GLP-1 sector [1] - CSPC will receive an upfront payment of USD 1.2 billion, with potential milestone payments for research reaching up to USD 3.5 billion and sales milestone payments up to USD 13.8 billion [1] - Additionally, CSPC is entitled to a sales commission based on the annual net sales of related products, with the total potential transaction amounting to USD 18.5 billion [1]

Core Viewpoint - The stock of Stone Pharmaceutical Group (01093) has fallen over 10%, currently trading at 9.72 HKD with a transaction volume of 2.563 billion HKD following the announcement of a strategic collaboration and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs [1] Group 1: Strategic Collaboration - Stone Pharmaceutical Group has signed a strategic collaboration and licensing agreement with AstraZeneca covering a clinical-ready long-acting GLP-1/GIP dual-target agonist project SYH2082 and three preclinical projects [1] - The agreement also includes plans for collaboration on an additional four new projects [1] Group 2: Financial Terms - The collaboration sets a new record for overseas business development transactions in the GLP-1 sector, with Stone Pharmaceutical Group receiving a prepayment of 1.2 billion USD [1] - The company is entitled to receive up to 3.5 billion USD in potential research milestone payments and up to 13.8 billion USD in potential sales milestone payments [1] - Additionally, Stone Pharmaceutical Group will earn a sales commission based on the annual net sales of related products, with potential total transaction value reaching up to 18.5 billion USD [1]

Investment Rating - The report assigns a positive investment rating to the company, highlighting its potential in the oncology sector with innovative drug candidates [7][36]. Core Insights - The company, 加科思, focuses on developing targeted therapies for cancer, particularly through its KRAS inhibitors and antibody-drug conjugates (ADCs) [4][8]. - The management team, led by founder Dr. Wang Yinxiang, has extensive experience in drug development, particularly in oncology [2][3]. - 加科思's lead product, 戈来雷塞 (Glecirasib), has been approved for the treatment of KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) in China, marking a significant milestone for the company [10][37]. - The company is advancing multiple clinical trials, including JAB-23E73, a pan-KRAS inhibitor, which is expected to enter pivotal studies in 2026 [36][37]. Company Overview - 加科思 is headquartered in Beijing with additional offices in Shanghai and Boston, employing over 210 staff, primarily in preclinical and clinical development [3]. - The company has established a robust pipeline focusing on the KRAS signaling pathway, with several drug candidates targeting different nodes of this pathway [4][5]. Product Pipeline - The product pipeline includes: - JAB-3312 (SHP2 inhibitor) and Glecirasib (KRAS G12C inhibitor) for NSCLC [12]. - JAB-BX600, a tADC targeting KRAS G12D, which is designed to enhance drug delivery and efficacy [23][24]. - JAB-BX467, an iADC that aims to convert cold tumors into hot tumors by recruiting immune cells [27][28]. Clinical Data - Glecirasib has shown promising clinical results, with a 49.6% objective response rate (ORR) and an 86.3% disease control rate (DCR) in a pivotal study for 2L NSCLC [10][11]. - The combination of Glecirasib and JAB-3312 in first-line NSCLC treatment demonstrated a 71% ORR, significantly outperforming standard therapies [12][13]. Financial Performance - The company reported a 100% increase in revenue for the first half of 2025, driven by sales from Glecirasib and collaboration agreements [35]. - The company maintains a strong cash position, with 1.07 billion yuan in cash and available credit to support ongoing clinical development [35]. Strategic Partnerships - 加科思 has entered into strategic partnerships, including a collaboration with 阿斯利康 for JAB-23E73, which includes significant milestone payments and revenue sharing [37].

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

阿斯利康将向许可方支付合计12亿美元的总首付款，其中巨石生物收取的首付款金额为总首付款金额的 35%。阿斯利康将根据许可区域范围内的开发、上市和销售等情况，向许可方支付相应里程碑款项。阿 斯利康将向许可方累计支付最高35亿美元的开发里程碑款项、最高138亿美元的销售里程碑款项。其 中，巨石生物将有权根据《战略合作与授权协议》所授权管线的实际情况收取相应的开发里程碑款项和 销售里程碑款项。 本次交易有利于加快公司相关创新药管线在全球范围内的开发和商业化进程，对公司深化全球布局、加 速创新成果转化具有重要意义。本次交易将持续优化公司现金流结构，加速前期研发投入回收，为后续 创新药管线的持续研发提供稳定的资金支持，高度契合公司加速打造领先的创新生物医药平台的长期发 展战略，有利于促进公司的长远可持续发展，对公司的未来经营发展将产生较大的积极影响。 新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以下简 称"巨石生物")及公司的关联方石药集团有限公司(以下简称"石药集团")、石药集团中奇制药技术(石家 庄)有限公司(以下简称"中奇制药")共同与阿斯利康于2026年1 ...